Is This The Biggest Threat to Isis Pharmaceuticals Stock?
Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis' drugs might face stiff competition. So are investors being overly optimistic?
This Market Could Grow 6250% in 10 Years
With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.
Dividend Stocks: 2 to Avoid, 1 to Buy
Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.
Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and
Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90